A double‐blind, randomized, placebo‐controlled, phase
            <scp>II</scp>
            trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

Werth, Victoria P.; Merrill, Joan T.

doi:10.1111/bjd.17344

Cited by 12 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ibrutinib, a selective BTK inhibitor, could potentially prove useful in the treatment of neuropsychiatric disease, such as SLE [ 111 ]. This inhibitor has already have already been approved for clinical use in hematological indications [ 112 ] and results from ongoing early phase clinical trials of BTK inhibitors in patients with SLE are eagerly awaited.…”

Section: Promising Targeted Therapiesmentioning

confidence: 99%

Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

Wang

Zhang

et al. 2022

JCM

View full text Add to dashboard Cite

Neuropsychiatric systemic lupus erythematosus (NPSLE) has a broad spectrum of subtypes with diverse severities and prognoses. Ischemic and inflammatory mechanisms, including autoantibodies and cytokine-mediated pathological processes, are key components of the pathogenesis of NPSLE. Additional brain-intrinsic elements (such as the brain barrier and resident microglia) are also important facilitators of NPSLE. An improving understanding of NPSLE may provide further options for managing this disease. The attenuation of neuropsychiatric disease in mouse models demonstrates the potential for novel targeted therapies. Conventional therapeutic algorithms include symptomatic, anti-thrombotic, and immunosuppressive agents that are only supported by observational cohort studies, therefore performing controlled clinical trials to guide further management is essential and urgent. In this review, we aimed to present the latest pathogenetic mechanisms of NPSLE and discuss the progress in its management.

show abstract

Section: Promising Targeted Therapiesmentioning

confidence: 99%

Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

Wang

Zhang

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Unfortunately, other therapeutic options, such as the inhibition of IL-23 and the use of baricitinib, have not provided sufficiently convincing data, despite the promising results obtained in phase II (ustekinumab) and phase III studies (baricitinib: BRAVE I) [ 54 , 55 ]. Hence, further studies and development programs of these drugs in SLE have been stopped.…”

Section: The Modern Treatment Of Sle: What About the Musculoskeletal ...mentioning

confidence: 99%

Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium

Ceccarelli

Govoni

Piga

et al. 2022

JCM

View full text Add to dashboard Cite

Musculoskeletal involvement is one of the most common manifestations of systemic lupus erythematosus (SLE), with a negative impact on both quality of life and overall prognosis. SLE arthritis can be classified into three different subtypes, with different prevalence and characteristic biomarkers and MRI findings. Identifying the pathogenetic mechanisms underlying musculoskeletal manifestations’ development is crucial to develop therapeutic strategies to suppress synovial inflammation, prevent erosions and deformities, and improve SLE patients’ quality of life. Hence, here we discuss the main pathogenetic mechanisms and therapeutic approaches of musculoskeletal manifestations of SLE from the 2022 International GISEA/OEG Symposium.

show abstract

“…Improvement in skin disease was assessed as an outcome, but did not show significant difference from the placebo group ( 34 ). While many of the SLE patients had cutaneous involvement, the baseline activity scores were low which can make it difficult to demonstrate improvement ( 35 ). Baricitinib was also being evaluated in two phase 3 SLE trials, but top-line results led to the decision to discontinue the phase 3 development program in lupus.…”

Section: Therapies That Failed In Clinical Trialsmentioning

confidence: 99%

Emerging Therapies in Cutaneous Lupus Erythematosus

et al. 2022

View full text Add to dashboard Cite

Cutaneous lupus erythematosus (CLE) is an autoimmune disease that can occur with or without underlying systemic lupus erythematosus (SLE) and often has a profoundly negative impact on patient quality of life. There is substantial need for new and more effective therapies to treat CLE. CLE has a multifactorial pathogenesis that involves several key immune cells and pathways, including abnormalities in innate (e.g., type 1 interferon pathways) and adaptive immune responses (e.g., B and T cell autoreactivity), presenting multiple opportunities for more targeted therapies that do not require immunosuppression. Here we review several emerging therapies and their efficacy in CLE. Anifrolumab and belimumab have both been approved for the treatment of SLE in recent years, and clinical trial evidence suggests some forms of CLE may improve with these agents. Therapies currently in development that are being evaluated with CLE-specific outcome measures include BIIB059 and VIB7734, which target plasmacytoid dendritic cells (pDCs), and iberdomide, a cereblon modulator. These novel therapies all have previously demonstrated clinical benefit in some forms of CLE. Other therapies which target molecules believed to play a role in CLE pathogenesis, such as Janus kinases (JAKs), spleen tyrosine kinase (SYK), interferon γ (IFNγ), IL-12, and IL-23, have been evaluated in lupus clinical trials with skin-specific outcomes but failed to meet their primary endpoints.

show abstract

A double‐blind, randomized, placebo‐controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus

Cited by 12 publications

References 12 publications

Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus

Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium

Emerging Therapies in Cutaneous Lupus Erythematosus

Contact Info

Product

Resources

About